Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9135317 | 0.87 | CES2 (0.39) | CES2CES1ALDH1A1 | |
| SCHEMBL996758 | 0.86 | CES2 (0.43) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL1657 | 0.83 | CES2 (0.48) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL6538271 | 0.80 | CES2 (0.46) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL2295776 | 0.80 | ALDH1A1 (0.39) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL10920457 | 0.78 | CES2 (0.39) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL19307720 | 0.77 | CES2 (0.48) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL505527 | 0.76 | MEN1 (0.33) | CES2CES1 | |
| SCHEMBL10671409 | 0.76 | ESR1 (0.39) | CES2CES1ALDH1A1ALOX15 | |
| SCHEMBL9320500 | 0.76 | CES2 (0.32) | CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240376123-A1 | KRAS G12D INHIBITORS AND USES THEREOF | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2024-11-14 | — | — | US | disclosed |
| CN-117242079-A | KRAS G12D inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023001141-A1 | KRAS G12D INHIBITORS AND USES THEREOF | SHANGHAI ZION PHARMA CO. LIMITED (CN) | 2023-01-26 | — | — | WO | disclosed |
| US-5169853-A | Antibacterial agents; administering to mammals for infection | STERLING DRUG INC. (US) | 1992-12-08 | — | — | US | disclosed |
| US-5075319-A | Bactericides | STERLING DRUG INC. (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0417669-A2 | Pyridinyl-quinolone compounds, their preparation and use | STERLING WINTHROP INC. (US) | 1991-03-20 | — | — | EP | disclosed |
| US-4839355-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1989-06-13 | — | — | US | disclosed |
| EP-0309789-A1 | 4-Oxo-3-quinolinecarboxylic acids useful as antibacterial agents and preparation thereof | STERLING WINTHROP INC. (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0306860-A2 | 4-Oxo-3-Quinolinecarboxylic acids useful as antibacterial agents and preparation thereof | STERLING WINTHROP INC. (US) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376123-A1 | KRAS G12D INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | CES2 4851/4885CES1 3211/4885ALDH1A1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.